Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCTID	NCT05672121 (View at clinicaltrials.gov)
Description	KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision. (Show More)
Development Status	Active
Indication	Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term	DOID:10871
Compound Name	KH631
Sponsor	Chengdu Origen Biotechnology Co., Ltd.
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	42
Results Posted	Not Available

Target Gene/Variant	VEGFR1/R2 fusion protein
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV8
Editor Type	none
Dose 1	5 undisclosed dose levels (200ul/dose)
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	1
Locations	China